Tritonpoint Wealth LLC Invests $2.04 Million in Castle Biosciences, Inc. (NASDAQ:CSTL)

Tritonpoint Wealth LLC bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 94,356 shares of the company's stock, valued at approximately $2,036,000. Tritonpoint Wealth LLC owned about 0.35% of Castle Biosciences as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its stake in shares of Castle Biosciences by 351.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,110 shares of the company's stock valued at $67,000 after buying an additional 2,421 shares during the last quarter. Perkins Capital Management Inc. grew its stake in shares of Castle Biosciences by 10.2% during the fourth quarter. Perkins Capital Management Inc. now owns 32,140 shares of the company's stock valued at $694,000 after buying an additional 2,980 shares during the last quarter. Public Employees Retirement System of Ohio grew its stake in shares of Castle Biosciences by 22.9% during the third quarter. Public Employees Retirement System of Ohio now owns 100,254 shares of the company's stock valued at $1,693,000 after buying an additional 18,679 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Castle Biosciences by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,439,388 shares of the company's stock valued at $24,311,000 after buying an additional 11,967 shares during the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Castle Biosciences by 31.3% during the third quarter. American Century Companies Inc. now owns 17,631 shares of the company's stock valued at $298,000 after buying an additional 4,201 shares during the last quarter. Institutional investors own 92.60% of the company's stock.

Insiders Place Their Bets

In other Castle Biosciences news, Director Daniel Bradbury sold 2,074 shares of the firm's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $23.20, for a total value of $48,116.80. Following the completion of the sale, the director now directly owns 33,870 shares in the company, valued at $785,784. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Derek J. Maetzold sold 2,295 shares of Castle Biosciences stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $20.27, for a total transaction of $46,519.65. Following the completion of the transaction, the insider now directly owns 69,806 shares in the company, valued at $1,414,967.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Bradbury sold 2,074 shares of Castle Biosciences stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $23.20, for a total transaction of $48,116.80. Following the transaction, the director now owns 33,870 shares of the company's stock, valued at $785,784. The disclosure for this sale can be found here. Insiders sold 36,563 shares of company stock worth $766,053 over the last three months. Company insiders own 7.70% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. KeyCorp raised their price objective on Castle Biosciences from $25.00 to $28.00 and gave the company an "overweight" rating in a research note on Friday, March 1st. Scotiabank increased their target price on shares of Castle Biosciences from $33.00 to $37.00 and gave the stock a "sector outperform" rating in a report on Friday, March 1st. Finally, Guggenheim started coverage on shares of Castle Biosciences in a report on Thursday, December 14th. They set a "buy" rating and a $25.00 target price for the company.

Castle Biosciences Stock Down 2.0 %

Shares of Castle Biosciences stock traded down $0.42 during trading on Friday, reaching $20.82. 154,307 shares of the stock were exchanged, compared to its average volume of 214,537. Castle Biosciences, Inc. has a 1 year low of $9.26 and a 1 year high of $26.70. The stock's fifty day moving average is $22.29 and its 200 day moving average is $19.64. The firm has a market cap of $571.51 million, a price-to-earnings ratio of -9.64 and a beta of 0.93.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.74. Castle Biosciences had a negative net margin of 26.15% and a negative return on equity of 14.92%. The business had revenue of $66.12 million during the quarter, compared to analyst estimates of $51.32 million. Equities analysts forecast that Castle Biosciences, Inc. will post -2.41 earnings per share for the current year.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.